Drugs / Zelenectide pevedotin

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT04561362 Jul 2020 → Mar 2026 overdue hormone receptor-positive breast cancer, non-small cell lung carcinoma, ovarian neoplasm, triple-negative breast carcinoma +1 BicycleTx Limited Active not recruiting No outcome recorded
Phase 24 trials
Phase 2 NCT07681674 Aug 2026 → May 2030 expected cancer BicycleTx Limited Not yet recruiting No outcome recorded
Phase 2 NCT06933329 Jul 2025 → Aug 2028 expected non-small cell lung carcinoma BicycleTx Limited Active not recruiting No outcome recorded
Phase 2 NCT06840483 Mar 2025 → Jun 2028 expected breast cancer BicycleTx Limited Active not recruiting No outcome recorded
Phase 2 NCT06225596 Jan 2024 → Mar 2028 expected urothelial carcinoma BicycleTx Limited Active not recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as zelenectide pevedotin Zelenectide pevedotin (BT8009) is a Bicycle Drug Conjugate” PMID 41197088 Nov 2025
4

NCT06840483

NCT06933329

NCT07681674

NCT06225596

Known as BT8009 “Zelenectide pevedotin (BT8009)” NCT06840483
1

NCT04561362

Known as Zelenectida pevedotina ChEMBL registry synonym — accepted as the source's own label CHEMBL5314903
Known as Zelenectide pavedotin ChEMBL registry synonym — accepted as the source's own label CHEMBL5314903
Known as Zelenectide pevedotine ChEMBL registry synonym — accepted as the source's own label CHEMBL5314903
Modality Peptide “highly selective Nectin-4-targeting Bicycle peptidePMID 41197088 Nov 2025
Modality Protein / enzyme biologic CHEMBL5314903
Route Intravenous “received zelenectide pevedotin intravenously at 2.5, 5.0, or 7.5 mg/m2” PMID 41197088 Nov 2025